**From:** Gideon Lapidoth

**Sent:**  **To:**  **Cc:** Orly Savion, Jacob, Magic **Subject:** A Novel Method for Increasing Protein and Peptide Based Drugs Half-Life [1555]

Dear **Dr. Subramanyam,**

My name is Dr. Gideon Lapidoth and I am a licensing assistant at YEDA R&D, the commercial arm of the Weizmann Institute. We are an academic institution looking for partners to license and bring our innovation forward to the market. We have identified a technology from Profs. Yoram Shechter and Matityahu Fridkin that aligns with **Pfizer's** interests - engineered prolonged-acting prodrugs via albumin-binding probes.

I have attached a brief non-confidential summary to this email.

If you would like to learn more about this technology or if you would like to receive any additional non confidential/confidential (under NDA) information please contact Dr. Orly Savion:

Orly Savion, PhD  
Director of Business Development – Life Sciences

Tel: +972.8.9344374

Email:  
Orly.Savion@Weizmann.ac.il

Best regards,  
  
Gideon

Dr. Gideon Lapidoth

Licensing assistant  
[gideon.lapidoth@weizmann.ac.il.](http://gideon.lapidpoth@weizmann.ac.il.)   
[www.YedaRnD.com](http://www.yedarnd.com/)